mm pattern 4 on biopsy far superior predictor of prostate cancer outcome than stage, grade, PSA, cores. We show using mm criteria rather than "favorable intermediate risk" would increase the number of US men eligible for active surveillance by >50,000. pubmed.ncbi.nlm.nih.gov/42830647/

"When we tell a patient they have prostate cancer, we mean the pathologist has looked at prostate biopsy cores under a microscope and saw areas without a basal cell layer; what the patient hears, however, is something entirely different" academic.oup.com/jnci/advance...

Helping patients make better choices by relabeling pattern 3 prostate disease as noncancerous

I have sat in consulting rooms listening to my surgeon colleagues explain to a patient their diagnosis, prognosis, and recommended management. Every time,

academic.oup.com

Netto et al published an argument against relabeling pattern 3 prostate disease as pre-cancerous: pattern 3 but not benign shares “canonical molecular alterations” with pattern 4. A literature review shows this to be false @uroegg @dr_coops bjui-journals.onlinelibrary.wiley.com/doi/10.1111/...

Is Gleason pattern 3 cancer? Molecular features do not distinguish pattern 3 from benign tissue

Click on the article title to read more.

bjui-journals.onlinelibrary.wiley.com

Can anyone at AMA please explain to be the rationale of insisting on two significant figures for high p values but one significant figure for lower p values? The 4 in p=0.34 tells us nothing; truncating the 4 so p=0.034 is changed to 0.03 is losing information.

On the left, Robin meets his hero, Jimmy Mickle, at frisbee summer camp, 2018. On the right, Robin and Jimmy after Robin's team, San Francisco Revolver, defeats Jimmy's (New York Pony) in the World Ultimate Club Championship final.

Almost all high-income countries have a national policy recommending shared decision-making before PSA screening. We show: a) this recommendation never justified by evidence; b) best evidence is PSA screening not a preference-sensitive decision. journals.sagepub.com/eprint/UP9VV...

Should there be informed decision-making for prostate cancer screening? An analysis of preference sensitivity - Andrew Vickers, Sigrid Carlsson, 2026

Background Almost all national guidelines groups recommend that individual men make an informed personal decision about whether to be screened for prostate canc...

journals.sagepub.com

Generally assumed population-based PSA screening = increased overdiagnosis. But already lots of PS testing going on. In a modeling study, we show organized screening would reduce PSA tests, overdiagnsosis compared to current disorganized approach onlinelibrary.wiley.com/doi/10.1002/...

Effect of Implementing Population‐Based Prostate‐Specific Antigen Screening on Testing Rates and Prostate Cancer Overdiagnosis in England: A Statistical Modelling Study

We undertook a statistical modeling study to determine the effect of implementing population-based prostate-specific antigen (PSA) screening in England on overdiagnosis and PSA testing rates in compa...

onlinelibrary.wiley.com

Can everyone stop using the term "real world data" and just be precise about setting, participants and interventions? grandroundsinurology.com/the-reality-...

I've long been suspicious of "regret" as an endpoint. This is principally because decisional regret is predicated on the (improbable) understanding of outcome under the counterfactual. New paper shows regret is basically explained by "I had a bad outcome". pubmed.ncbi.nlm.nih.gov/42429300/

Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study - PubMed

Surgical decision regret after RP is primarily driven by postoperative functional outcomes rather than oncological results or surgical approach. Optimising functional recovery and managing patient exp...

pubmed.ncbi.nlm.nih.gov

Hiring right now and the surnames on our shortlist have the following origins: Jewish, Chinese, Irish, West African, East European, English, South Asian, Spanish. What a joy to live in a country where we get so many different histories and perspectives.

Hasn’t it been amazing to see teams from the minor footballing countries doing so well at the world cup, even if they come up short? I refer to Morocco, Egypt, Cape Verde and, of course, England.

When I report that I am doing a randomized trial, this is in distinction to a study with non-randomized or historical controls. But when a researcher claims to be analyzing "real world data", this is in distinction to what exactly?

Looking for the best papers on the positive and negative likelihood ratio for prostate MRI. What is LR+ and LR- separately for PIRADS 3, 4 and 5? Problem is, this can only be derived from a study where everyone had a biopsy or long-term follow-up.

Has anyone been noticing folks are starting to say "numerically superior" to describe results that are not statistically significant?

Can someone explain to be how, in meta-analysis, leave-one-out methodology, has anything to do with exploring the sources of heterogeneity?

One of my true heroes. She managed to find a work around to a catch-22 that male doctors had created to prevent women becoming doctors.

Admirable Women@admirablewomen.bsky.social · 4mo ago

Physician & suffragist Elizabeth Anderson was born #OTD in 1836. She was the: * First woman to qualify in the UK as a physician & surgeon & first MD in France * Co-founder of the first hospital staffed by women * First dean of a British medical school * First female mayor in the #UK #WomenInSTEM

Lots of interesting arguments against removing "cancer" label from pattern 3 prostate disease. For instance, pattern 3 involves basal cells & often has PTEN loss. Question now is whether these are a hill worth other people dying on. jamanetwork.com/journals/jam...

Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous

This decision analytical model study evaluates the effects of relabeling grade group 1 prostate cancer on prostate cancer mortality in the US.

jamanetwork.com

"Due to low sensitivity, PSMA-PET/CT without evidence of nodal disease does not obviate the need for PLND" BUT "PSMA-avid nodal disease portends ... nearly inevitable ... recurrence / progression, supporting treatment intensification." bjui-journals.onlinelibrary.wiley.com/doi/10.1111/...

Diagnostic and prognostic utility of PSMA‐PET/CT in node‐metastatic prostate cancer

Objective To measure the sensitivity of prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for detecting lymph node involvement (LNI) in patients under.....

bjui-journals.onlinelibrary.wiley.com

PSA screening reduces cancer-specific mortality (PCSM). Questions remain about effect on all-cause (OS). PSA could reduce PCSM not OS only with deaths from other causes, eg complications of surgery. Please reply with list of screening-induced causes of death.

If the UK were a US state, how would it rank? It depends entirely on what you measure! Fascinating table showing a startlingly different picture depending on the choice of metric. Source: www.linkedin.com/posts/diogo-...

Analysis of the CAP randomized trials demonstrates prostate cancer overdiagnosis is highly age dependent. Opportunistic screening policies have led to most PSA tests being in older men. These policies should be revaluated. onlinelibrary.wiley.com/doi/10.1002/ijc.70492

Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial

Uncertainty persists over whether the benefits of prostate-specific antigen (PSA) screening outweigh harms from overdiagnosis, a key barrier to population-wide adoption. Here, English male mortality ....

onlinelibrary.wiley.com

Accrual to cancer RCTs is very poor. Keeping the product (ie the trial) the same but changing the advertising has a very small effect doi.org/10.1002/cam4.... Alternatively , change the product pubmed.ncbi.nlm.nih.gov/39410769/: it is possible to rapidly accrue to large, single-center RCTs

Strategies for increasing accrual in cancer clinical trials: What is the evidence?

Introduction Despite the importance of clinical trial participation among cancer patients, few participate—and even fewer patients from ethnic and racial minoritized groups. It is unclear whether su.....

doi.org

Time to bring back a classic! I asked a journal editor for a date. She declined, but said I could date her sister if I paid $4,000.

Just saw geology undergraduate final presentations @carleton.edu Way better presentational, statistical and causal reasoning skills than at typical medical conferences. Why we aren’t teaching our fellows and residents better, given that, you know, lives are at stake?

Doing statistics well is hard. Avoiding egregious errors in analysis, reporting and interpretation isn't. Just read, understand and follow the guidelines. pubmed.ncbi.nlm.nih.gov/32451178/ pubmed.ncbi.nlm.nih.gov/37286459/ pubmed.ncbi.nlm.nih.gov/40914655/ pubmed.ncbi.nlm.nih.gov/30580902/

Guidelines for Reporting of Figures and Tables for Clinical Research in Urology - PubMed

In an effort to improve the presentation of and information within tables and figures in clinical urology research, we propose a set of appropriate guidelines. We introduce six principles: (1) include graphs only if they improve the reader's ability to understand the study findings; (2) think throug …

pubmed.ncbi.nlm.nih.gov

Just submitted a paper to "Diabetes & Metabolic Syndrome: Clinical Research & Reviews". Was asked by editor *before* they would peer review: my h-index ; all publications in past 12 months, along with impact factor of each journal in which they were published". #RealScience

pubmed.ncbi.nlm.nih.gov/29404569/

Statistical Code for Clinical Research Papers in a High-Impact Specialist Medical Journal - PubMed

Statistical Code for Clinical Research Papers in a High-Impact Specialist Medical Journal

pubmed.ncbi.nlm.nih.gov

Francisco Rodriguez-Sanchez@frodsan.bsky.social · 7mo ago

97% of the papers archived the data but only 35% archived the code. Most people are writing code but not sharing it. Time to bring up this again: scispace.com/pdf/publish-... (and if the code isn't good enough yet, maybe it's too early to publish the paper) #openscience #reproducibility #ecopubs

If only AI / ML had been around when I was training, I wouldn’t have had to learn about things like causal inference, how to evaluate prediction models or even, say, the importance of data quality. What a waste of time all that was!

Any suggestions as to great resources (lectures on YouTube, short didactic papers etc), to teach novice researchers about RCTs? Design, endpoints, consent, eligibility criteria, IRB etc etc any and all of it.

COULD EVERYONE PLEASE STOP USING RANDOM EFFECTS META-ANALYSIS WHEN COMBINING 3 OR 4 TRIALS? AND COULD REVIEWERS STOP DEMANDING IT?